全文获取类型
收费全文 | 246篇 |
免费 | 6篇 |
专业分类
儿科学 | 5篇 |
妇产科学 | 2篇 |
基础医学 | 10篇 |
口腔科学 | 6篇 |
临床医学 | 14篇 |
内科学 | 26篇 |
皮肤病学 | 2篇 |
神经病学 | 6篇 |
特种医学 | 96篇 |
外科学 | 28篇 |
综合类 | 7篇 |
预防医学 | 33篇 |
眼科学 | 1篇 |
药学 | 10篇 |
肿瘤学 | 6篇 |
出版年
2021年 | 3篇 |
2020年 | 1篇 |
2019年 | 1篇 |
2018年 | 2篇 |
2016年 | 1篇 |
2015年 | 4篇 |
2014年 | 7篇 |
2013年 | 5篇 |
2012年 | 5篇 |
2010年 | 5篇 |
2009年 | 4篇 |
2008年 | 5篇 |
2007年 | 9篇 |
2006年 | 9篇 |
2005年 | 3篇 |
2004年 | 10篇 |
2003年 | 11篇 |
2002年 | 8篇 |
2001年 | 10篇 |
2000年 | 3篇 |
1999年 | 5篇 |
1998年 | 11篇 |
1997年 | 9篇 |
1996年 | 10篇 |
1995年 | 6篇 |
1994年 | 11篇 |
1993年 | 6篇 |
1992年 | 1篇 |
1991年 | 3篇 |
1990年 | 4篇 |
1989年 | 6篇 |
1988年 | 9篇 |
1987年 | 6篇 |
1986年 | 9篇 |
1985年 | 8篇 |
1984年 | 3篇 |
1983年 | 5篇 |
1982年 | 7篇 |
1981年 | 4篇 |
1980年 | 12篇 |
1979年 | 1篇 |
1978年 | 3篇 |
1977年 | 1篇 |
1976年 | 3篇 |
1975年 | 2篇 |
1973年 | 1篇 |
排序方式: 共有252条查询结果,搜索用时 258 毫秒
151.
152.
153.
154.
155.
156.
Christopher J. Destache Pharm.D. Catherine B. Pakiz M.T. Karl Kersting D.VM. 《Pharmacotherapy》1997,17(5):985-989
Minimum inhibitory concentrations (MICs) and minimum bactericidal concentrations (MBCs) of azithromycin against reference strains of Streptococcus pneumoniae ATCC 49619, Neisseria meningitidis ATCC 13090, and Haemophilus influenzae ATCC 49247 were determined by the macrodilution broth method with and without 10% bovine cerebrospinal fluid (CSF) supplementation. The MICs and MBCs were within one to two dilutions for N. meningitidis and S. pneumoniae, and no difference was observed for H. influenzae. Time-kill curves demonstrated enhanced killing by azithromycin when 10% bovine CSF was added to media for N. meningitidis. The minimum azithromycin concentration for a greater than 3 log10 reduction in inoculum with bovine CSF was 0.03 μg/ml and without CSF was 0.12 μg/ml, a 3-fold difference. Killing was not significantly different for either H. influenzae nor S. pneumoniae. (Pharmacotherapy 1997;17(5);985–989) 相似文献
157.
BACKGROUND: Alloimmunized refractory thrombocytopenic patients often require HLA-matched platelet transfusions. As the HLA system is very polymorphic, sufficient HLA-matched donors are not available for every patient. STUDY DESIGN AND METHODS: In vitro elution techniques with citric acid incubation of platelets at pH 3.0 showed that platelets lose expression of HLA, whereas platelet-specific glycoproteins are preserved. This technique was modified for clinical use. Random-donor platelet concentrates were incubated with citric acid, subsequently washed, and transfused to two patients. RESULTS: Platelet-specific glycoproteins were unaffected, and HLA expression decreased generally to below 25 percent of the initial expression. One alloimmunized patient who was without compatible donors because of a rare HLA type underwent repeated transfusions with acid-treated platelets. In contrast to the results with random-donor platelet transfusions, posttransfusion increments up to 47 × 10(9) per L were obtained with acid-treated platelets, and profuse gastrointestinal bleeding was stopped, while multiple skin hemorrhages were resolved. No side effects were observed. A second patient developed a severe transfusion reaction without platelet increment after one transfusion with acid-treated platelets expressing 30 percent of the original HLA antigens. Further transfusions were not given. CONCLUSION: Standardization of the acid elution technique and validation of the technique in patients is necessary. The results suggest, however, that HLA-eluted platelets prepared under specified conditions may gain a place in platelet transfusion therapy. 相似文献
158.
159.
160.
Preparation and identification of a population of antibodies that recognize carbodiimide-modified heparin 总被引:2,自引:0,他引:2
Protein-heparin complexes, prepared by a water-soluble carbodiimide coupling technique, were used to produce anti-heparin antibodies in rabbits. Antiserums that recognized carbodiimide-treated heparin, but not untreated heparin, were obtained. Carbodiimide-treated heparan sulfate exhibited 10% to 20% cross-reactivity compared with a similarly treated heparin, whereas there was no cross-reactivity with five other carbodiimide-treated mucopolysaccharides. 3H-1-ethyl-3-(3- trimethylammoniumpropyl) carbodiimide iodide was used to demonstrate that carbodiimide forms a stable adduct with heparin and other mucopolysaccharides. Using an antibody fraction that eluted from 1- ethyl-3-(3-trimethylammoniumpropyl) carbodiimide iodide-treated heparin- Sepharose with 2 mol/L KI, it was demonstrated that, for the antibody population studied, the addition of one carbodiimide per heparin molecule resulted in complete epitope expression without loss of anticoagulant activity. The addition of up to eight additional carbodiimide molecules to heparin did not increase the extent of epitope formation, although anticoagulant activity was lost. Except for heparan sulfate, the addition of radiolabeled carbodiimide to other mucopolysaccharides did not result in epitope formation. These data demonstrate that antibodies to an epitope derived from heparin can be formed, that the epitope is fully expressed while anticoagulant activity is present, and that the antibody is specifically directed against an altered portion of the polysaccharide. 相似文献